May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Macugen in Retinopathy of Prematurity
Author Affiliations & Notes
  • M.T. Trese
    Associated, Royal, MI
  • A. Capone, Jr.
    Associated Retinal Consultants, Royal Oak, MI
  • K. Drenser
    Associated Retinal Consultants, Royal Oak, MI
  • Footnotes
    Commercial Relationships  M.T. Trese, None; A. Capone, None; K. Drenser, None.
  • Footnotes
    Support  ROPARD
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2330. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.T. Trese, A. Capone, Jr., K. Drenser; Macugen in Retinopathy of Prematurity . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2330.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To determine if Macugen will quiet VEGF activity in retinopathy of prematurity (ROP). This was done with a limited IND.

Methods: : 3 eyes of children less than 36 weeks postmenstrual age with bilateral severe posterior ROP or vascularly active eyes following laser therapy had one eye treated with a Macugen injection one week apart. The fellow eye served as a control.

Results: : All 3 eyes showed quieting of the vascular activity. In eyes that developed retinal detachment, vitrectomy was possible in vascularly quiet eyes.

Conclusions: : Macugen can reduce vascular activity in ROP and although retinal detachment can still occur, the vascularly quiet eye allows early and potentially more successful vitrectomy. Injection techniques, bolus and dose, timing and regression pattern will be presented.

Keywords: retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.